New pill shows promise for controlling rare hormone disorder
NCT ID NCT03257462
Summary
This study tested whether a new oral medication called SPR001 could help adults with classic congenital adrenal hyperplasia (CAH) better control their hormone levels. Twenty-four participants took increasing doses of the pill over six weeks while researchers monitored safety and hormone changes. The goal was to see if SPR001 could reduce problematic hormone levels that cause symptoms in this genetic condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spruce Biosciences Clinical Site
Orange, California, 92123, United States
-
Spruce Biosciences Clinical Site
San Diego, California, 92123, United States
-
Spruce Biosciences Clinical Site
Melbourne, Florida, 32935, United States
-
Spruce Biosciences Clinical Site
Atlanta, Georgia, 30046, United States
-
Spruce Biosciences Clinical Site
Indianapolis, Indiana, 46202, United States
-
Spruce Biosciences Clinical Site
Ann Arbor, Michigan, 48109, United States
-
Spruce Biosciences Clinical Site
Minneapolis, Minnesota, 55414, United States
-
Spruce Biosciences Clinical Site
Las Vegas, Nevada, 89148, United States
-
Spruce Biosciences Clinical Site
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.